Why is this ASX All Ords biotech share crashing 12% today?

This biotech is having a day to forget on Tuesday…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day.

In afternoon trade, the biotechnology company's shares are down 12% to $1.48.

This makes the Paradigm share price one of the worst performers on the All Ordinaries index today.

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

Why is the Paradigm share price sinking?

Investors have been hitting the sell button on Tuesday after Paradigm announced the surprise exit of its CEO and managing director, Marco Polizzi.

According to the release, Mr Polizzi has stepped down from his role immediately and will cease employment with the company on 20 February.

Paradigm only announced the appointment of Polizzi at the end of May, with the experienced pharmaceutical industry executive commencing in the role on 1 July. At the time, the company hyped up his appointment, describing him as "a CEO with the skills to fully unlock the commercial value of the company."

No reason was given for the CEO's exit after just a few months with the company. Nor did Polizzi leave a parting comment, which is never a good look and could potentially be an indication of boardroom tensions.

What now?

The Paradigm board has acted quickly and appointed the company's founder and non-executive chairman Paul Rennie as its new leader. He said:

I am pleased to advise that the personal circumstances that originally required my stepping down from the Managing Director role in 2021, have now been successfully resolved. I look forward to working closely again with the Paradigm executive team and the Board in continuing our journey together.

Following today's decline, the Paradigm share price has now lost almost a third of its value over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why this ASX healthcare share is a retiree's dream for FY27

This defensive business is giving investors rising dividends.

Read more »

Two scientists analysing results on a computer screen.
Broker Notes

Up 88%! Why CSL shares remain an 'appealing' buy today

A top analyst forecasts more outperformance from CSL’s surging shares.

Read more »

Two scientists analysing results on a computer screen.
Earnings Results

Monash IVF Group earnings: FY26 profit slips, outlook improves

The company posted weaker FY26 profit but ends year with improving momentum, dividend, and outlook for growth.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Healthcare Shares

Bell Potter says this ASX healthcare share could rise 200%+

The broker has good things to say about this growing stock.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

4DMedical share price rises as FY26 revenue climbs, losses moderate

4DMedical lifted revenue 21% and improved its adjusted net loss for FY26, while investing in new AI-driven medical imaging solutions.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems has teamed up with Philips to launch a new MR-guided cardiac interventions lab, targeting broader clinical adoption.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Why now is the time to buy low on these ASX healthcare shares with up to 84% upside

These two stocks have big upside.

Read more »

Silver dice with buy and sell written on them on top of stock market charts.
Healthcare Shares

CSL shares have surged 49%: Are brokers finally turning bullish?

CSL’s recovery is gathering pace, but has the share price already priced in the turnaround?

Read more »